ADVERSE-EFFECTS OF DIURETICS

被引:4
作者
FREIS, ED
机构
[1] Veterans Administration, Georgetown University Medical School, Washington, District of Columbia
[2] Department of Veterans Affairs Medical Center, Hypertension Research Clinic, Washington, District of Columbia, 20422
关键词
D O I
10.2165/00002018-199207050-00004
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
Analysis of the available evidence indicates that diuretics do not increase coronary heart disease morbidity and mortality. The multiclinic trials supporting the cardiotoxicity hypothesis are few in number and flawed in design. The majority of the trials, including the well designed trials, indicate no excess of coronary heart disease (CHD) events in diuretic-treated patients compared with those given other drugs or placebo. Recent studies indicate no increase in cardiac arrhythmias after diuretic treatment. Also, although depletion of intracellular potassium and magnesium occurs in patients with congestive heart failure even without diuretics, intracellular concentration of these ions is not significantly reduced by diuretics in patients with uncomplicated hypertension. Modest elevations of serum cholesterol may occur during the first 6 to 12 months of treatment with thiazide diuretics. However, after this time these elevations fall to or below the pretreatment level. The fall may be greater in patients receiving other drugs but the differences are small and their clinical significance is questionable. The incidences of hyperglycaemia and diabetes were only minimally increased in long term clinical trials while the importance of hyperinsulinism and insulin resistance in causing CHD remains unproven in patients. Thiazides remain, therefore, a safe and effective treatment for patients with hypertension.
引用
收藏
页码:364 / 373
页数:10
相关论文
共 59 条
  • [1] Alcazar J., Ruilope L., de Ladron Guevara P., Et al., Interrelationship between uric acid, cholesterol and triglycerides in essential hypertension, (1982)
  • [2] Amery A., Birkenhager W., Brixko P., Et al., Mortality and morbidity results from the European Working Party on High Blood Pressure in the Elderly Trial, Lancet, 1, pp. 1349-1354, (1985)
  • [3] Ames R.P., Hill P., Elevation of serum lipids during diuretic therapy for hypertension, American Journal of Medicine, 61, pp. 748-757, (1976)
  • [4] Araoye M.A., Khatri I.M., Yao L.L., Freis E.D., Leucocyte intracellular cations in hypertension: effect of antihypertensive drugs, American Heart Journal, 98, pp. 731-738, (1978)
  • [5] Bergstrom J., Hultman E., Solheim S.B., The effect of mefruside on plasma and muscle electrolytes and blood pressure in normal subjects and in patients with essential hypertension, Acta Medica Scandinavica, 194, pp. 427-432, (1973)
  • [6] Berglund G., Anderson O., Widgren B., A low-dose antihypertensive treatment with a thiazide diuretic is not diabetogenic
  • [7] a 10-year controlled trial with bendroflamethiazide, Journal of Hypertension, 4, (1986)
  • [8] Christlieb A.R., Treating hypertension in patients with diabetes mellitus, Medical Clinics of North America, 66, pp. 1373-1388, (1982)
  • [9] Cort J.H., Mathews H.L., Potassium deficiency in congestive heart failure: three cases with hyponatremia including results of potassium replacement in one case, Lancet, 1, pp. 1202-1206, (1954)
  • [10] Curtis J., Harrigan F., Ahearn D., Varney B., Sandier S.G., Et al., Chlorothalidone induced hyperosmolar, hyperglycemic, non-ketotic coma, Journal of the American Medical Association, 220, pp. 1592-1593, (1972)